| Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin I Gouin‐Thibault, X Delavenne, A Blanchard, V Siguret, JE Salem, ... Journal of Thrombosis and Haemostasis 15 (2), 273-283, 2017 | 175 | 2017 |
| Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies S Laporte, C Chapelle, P Caillet, MN Beyens, F Bellet, X Delavenne, ... Pharmacological research 118, 19-32, 2017 | 151 | 2017 |
| Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays I Gouin-Thibault, C Flaujac, X Delavenne, S Quenet, MH Horellou, ... Thrombosis and haemostasis 112 (02), 240-248, 2014 | 144 | 2014 |
| Prevalence of poor biological response to clopidogrel N Mallouk, C Labruyère, JL Reny, C Chapelle, M Piot, P Fontana, JC Gris, ... Thrombosis and haemostasis 107 (03), 494-506, 2012 | 109 | 2012 |
| Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients S Perinel, M Launay, É Botelho-Nevers, É Diconne, A Louf-Durier, ... Clinical infectious diseases 71 (16), 2227-2229, 2020 | 105 | 2020 |
| UPLC MS/MS assay for routine quantification of dabigatran–a direct thrombin inhibitor–in human plasma X Delavenne, J Moracchini, S Laporte, P Mismetti, T Basset Journal of pharmaceutical and biomedical analysis 58, 152-156, 2012 | 96 | 2012 |
| A semi‐mechanistic absorption model to evaluate drug–drug interaction with dabigatran: application with clarithromycin X Delavenne, E Ollier, T Basset, L Bertoletti, S Accassat, A Garcin, ... British journal of clinical pharmacology 76 (1), 107-113, 2013 | 93 | 2013 |
| Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study X Delavenne, P Mismetti, T Basset Journal of pharmaceutical and biomedical analysis 78, 150-153, 2013 | 71 | 2013 |
| In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition S Hodin, T Basset, E Jacqueroux, O Delezay, A Clotagatide, N Perek, ... European journal of drug metabolism and pharmacokinetics 43, 183-191, 2018 | 65 | 2018 |
| Exposure–response relationship of tranexamic acid in cardiac surgery: a model-based meta-analysis PJ Zufferey, J Lanoiselee, B Graouch, B Vieille, X Delavenne, E Ollier Anesthesiology 134 (2), 165-178, 2021 | 54 | 2021 |
| UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: application to pharmacokinetic study X Delavenne, L Juthier, B Pons, C Mariat, T Basset Clinica chimica acta 412 (1-2), 59-65, 2011 | 49 | 2011 |
| Assessment of HBEC-5i endothelial cell line cultivated in astrocyte conditioned medium as a human blood-brain barrier model for ABC drug transport studies C Puech, S Hodin, V Forest, Z He, P Mismetti, X Delavenne, N Perek International journal of pharmaceutics 551 (1-2), 281-289, 2018 | 48 | 2018 |
| Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants G Jourdi, M Delrue, A Stepanian, J Valaize, G Foulon-Pinto, J Demagny, ... Thrombosis Research 184, 86-91, 2019 | 45 | 2019 |
| Pharmacological characterization of the 3D MucilAir™ nasal model C Mercier, E Jacqueroux, Z He, S Hodin, S Constant, N Perek, D Boudard, ... European Journal of Pharmaceutics and Biopharmaceutics 139, 186-196, 2019 | 43 | 2019 |
| Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism L Bertoletti, E Ollier, C Duvillard, X Delavenne, MN Beyens, ... Pharmacological research 118, 33-42, 2017 | 43 | 2017 |
| Individualized PK‐based prophylaxis in severe haemophilia Y Dargaud, X Delavenne, DP Hart, S Meunier, P Mismetti Haemophilia 24, 3-17, 2018 | 37 | 2018 |
| Ultra‐performance LC MS/MS method for quantification of clopidogrel active metabolite X Delavenne, T Basset, P Zufferey, N Malouk, S Laporte, P Mismetti Journal of separation science 33 (13), 1968-1972, 2010 | 37 | 2010 |
| In vitro and in vivo evaluation of drug–drug interaction between dabigatran and proton pump inhibitors E Ollier, S Hodin, T Basset, S Accassat, L Bertoletti, P Mismetti, ... Fundamental & clinical pharmacology 29 (6), 604-614, 2015 | 36 | 2015 |
| Intravenous tranexamic acid bolus plus infusion is not more effective than a single bolus in primary hip arthroplasty: a randomized controlled trial PJ Zufferey, J Lanoiselée, C Chapelle, DB Borisov, JY Bien, P Lambert, ... Anesthesiology 127 (3), 413-422, 2017 | 35 | 2017 |
| Effect of activated charcoal on rivaroxaban complex absorption E Ollier, S Hodin, J Lanoiselée, J Escal, S Accassat, E De Magalhaes, ... Clinical Pharmacokinetics 56, 793-801, 2017 | 35 | 2017 |
silvy laportesaint-etienne在 chu-st-etienne.fr 的电子邮件经过验证
